2. Evidence of the reversibility of airflow limitation meets the requirements of the protocol;
3. Pre-bronchodilator forced expiratory volume (FEV1) meets the requirements of the protocol at screening and baseline;
4. Asthma Control Questionnaire 5-question version (ACQ-5) score≥1.5 at screening and baseline;
5. The participants agree to use highly effective contraception methods from the moment of signing of the ICF to 3 months after the last dose of the investigational product.
You may not be if
1. Concomitant respiratory diseases that, as determined by investigators, may affect the evaluation of therapeutic effects or safety of the investigational product;
2. A participant who experiences a severe asthma exacerbation at any time from 4 weeks prior to the screening up to and including the baseline;
3. Allergic to any component of the investigational product or intolerant to basis treatment;
4. Ongoing use of prohibited treatments. Washout periods detailed in the protocol have to be adhered to;
5. Other reasons the investigators believe that the participants are not suitable to enrolled in this study.
Clareo Health | A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Asthma
